Xenothera
Desconocido
BRIGHT: Treat severe cases of infection at COV with XAV 19
XENOTHERA
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimize...
2020-07-27 - 2022-12-31 | Financiado
2020-07-27 - 2022-12-31 | Financiado
POLYBOOST: POLYBOOST Renovating the Polyclonal Immunotherapy
XENOTHERA
tramitó un
H2020:
H2020-SMEInst-2016-2017
Immunotherapy is an essential field of medicine that allows clinicians to stimulate or to suppress the response of our immune system against...
2017-01-31 - 2017-03-31 | Financiado
2017-01-31 - 2017-03-31 | Financiado
* No se disponen de datos de la empresa actual.